Latest Progress In Cancer Treatment 2011 - Part I

                         Progress in Breast Cancer
Latest Progress In Cancer Treatment  2011

That occur annually in the United States and 182,000 in women with breast cancer is the most common female cancer. During their lifetimes are likely to be one of the six women to breast tumor development.

Fortunately, many women with breast cancer who has a normal lifespan. Prevention, early detection and improved treatment of malignant disease and the relative freedom that occurs in the range of near-normal life are combining.

Anticancer screening technique and adjuvant therapies has contributed to the greater use of advanced breast cancer survival and mortality rates are decreasing. Preventive measures to help reduce the risk of breast cancer for at least several months, regular exercise, limiting alcohol, maintaining a healthy weight, and breast-feeding are included.

Halaven
1. Halaven (eribulin) - approved by the FDA in November 2010, the sea-sponge - a product of the previously received an anthracycline and a taxane for the treatment of patients with metastatic breast cancer.




Faslodex


2. Faslodex (Fulvestrant) is a selective estrogen receptor down - regulator (SERD), and disease progression in women with postmenopausal hormone receptor - positive metastatic breast cancer, FDA approval of the following antiestrogen therapy. Initially, fulvestrant approved dose of 250 mg once-monthly administration, however, FDA has recently granted on the basis of fulvestrant 500 mg monthly for most of the positive results of two studies are acknowledged.

Progression of gastric cancer

Herceptin for gastric cancer
1. Herceptin (trastuzumab) - metastatic gastric cancer, trastuzumab is a biological agent "overexpress" HER2 is found to increase survival for patients with tumors. In one study it was found to significantly improve overall survival Trastuzumab.

Progression of pancreatic cancer

Targeted therapies have shown promise in pancreatic tumors as small molecule non-biological (artificial) agents are located. It is the function of tyrosine kinases, many of these agents in a number of cellular growth factor receptors, and rapamycin (mTOR) mammalian target of target. Sunitinib and everolimus: two molecularly target agents, such as randomized trials have shown benefit.

Sutent
1. Sutent (sunitinib) - Some advanced pancreatic tumors in a mouth of an active tyrosine kinase inhibitor. Sutent 171 placebo patients - a randomized controlled trial, administration, and the median progression free survival associated with a significant delay of six months.





Afinitor (everolimus)
2. Afinitor (everolimus) - Improved, 410 patients with advanced pancreatic cancer, some kind of placebo - controlled trial, median progression free survival is a significant barrier to six months relative to an mTOR inhibitor.

Progression of colorectal cancer

A KRAS proto - the adaptation of the most important step in the development of many cancers. KRAS / molecule, which acts on the switch, or activate growth factors involved in proliferation and malignant cell growth inhibition. Anticancer drugs are an essential amino acid and nucleotide substitution, Vectibix (panitumumab) and Erbitux (cetuximab) is a resistance, which are associated with KRAS proto - To enable the transition. The agent epidermal growth factor receptor (EGFR) target.

Erbitux (cetuximab)
1. Erbitux (cetuximab) - metastatic colorectal cancer, cetuximab is a large previous study to obtain a "p.G13D transition" patients survived longer than those of other K-RAS mutations are shown. A "p.G13D transition" and Erbitux for patients with moderate response, and wild - comparable to the overall survival of patients with Type K-RAS.

In Part II of this review, lung and prostate cancer development, additional topics, including developments in the treatment of cancer, will be addressed.


There was an error in this gadget